Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

Abroad (travel likely)Recruiting

Conditions

Febrile Neutropenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona, Spain
Complejo Asistencial Universitario de Salamanca, Salamanca, Salamanca, Spain
Contact: Study coordinator (Jesús Francisco Bermejo Martín, PhD) · jfbermejo@usal.es · +34923 29 45 41
Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain

Study leads

Jesús Francisco Bermejo Martín, MD PhD
Principal Investigator
Centro Asistencial Universitario de Salamanca (CAUSA)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients

Bloodstream Infection · Gram Negative Infections · Bacteraemia Caused by Gram-Negative Bacteria

Abroad (travel likely)Recruiting

Rozzano, Italy

ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy

Febrile Neutropenia

Abroad (travel likely)Recruiting

Cleveland, United States

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

Febrile Neutropenia

Abroad (travel likely)Recruiting

Taiyuan, China

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Primary/Secondary Prevention · High Risk for Febrile Neutropenia of Chemotherapy Regimens · Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia

Abroad (travel likely)RecruitingPHASE2

Zhengzhou, China